Relapse Prevention

Early Escalation of Acute Treatment Reduces Relapse Risk in Pediatric MOG Antibody-Associated Disease

By MedXY 08/25/2026

In pediatric myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), escalation of acute immunotherapy beyond steroids at first attack is linked to significantly fewer relapses within one year and mid-term follow-up, highlighting a critical therapeutic window to alter disease trajectory.

Allergy & Immunology Neurology news

Interleukin 6 Receptor Blockade: A Promising Strategy for Relapse Prevention in MOG Antibody-Associated Disease

By MedXY 07/16/2026

IL-6 receptor blockade significantly reduces relapse rates in MOG antibody-associated disease, showing comparable efficacy to high-dose IVIG with a favorable safety profile, supporting its role in relapse prevention.

Internal Medicine news Public Health

Beyond the Initial Quit: Mobile Chat Messaging as a Scalable Solution for Smoking Relapse Prevention

By MedXY 01/26/2026

Recent clinical trials demonstrate that mobile chat-based interventions, combining live counselors and chatbots, significantly reduce smoking relapse rates and improve long-term abstinence through personalized, real-time support and engagement tracking.

news Psychiatry

Slow Tapering with Psychological Support Matches Medication Continuation for Relapse Prevention in Remitted Depression

By MedXY 12/19/2025

A landmark network meta-analysis demonstrates that slow antidepressant tapering (>4 weeks) combined with psychological support is as effective as drug continuation in preventing relapse, providing a safe, evidence-based pathway for patients seeking to discontinue long-term treatment.